These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 7000090)

  • 1. Effects of bezafibrate on the serum lipoprotein lipid and apolipoprotein composition, lipoprotein triglyceride removal capacity and the fatty acid composition of the plasma lipid esters.
    Vessby B; Lithell H; Hellsing K; Ostlund-Lindqvist AM; Gustafsson IB; Boberg J; Ledermann H
    Atherosclerosis; 1980 Oct; 37(2):257-69. PubMed ID: 7000090
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of bezafibrate on plasma lipids, lipoproteins, apolipoproteins AI, AII and B and LCAT activity in hyperlipidemic, non-insulin-dependent diabetics.
    Prager R; Schernthaner G; Kostner GM; Mühlhauser I; Zechner R; Dorda W
    Atherosclerosis; 1982 Jun; 43(2-3):321-7. PubMed ID: 6810904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced LDL- and increased HDL-apoproteins in patients with hypercholesterolaemia under treatment with bezafibrate.
    Mordasini R; Riesen W; Oster P; Keller M; Middelhoff G; Lang PD
    Atherosclerosis; 1981 Oct; 40(2):153-8. PubMed ID: 6796096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of bezafibrate on the composition of very low density lipoproteins in type IV hyperlipoproteinemia.
    Schwandt P; Weisweiler P; Drosner M; Janetschek P
    Atherosclerosis; 1982 Apr; 42(2-3):245-9. PubMed ID: 7073803
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of bezafibrate on receptor-mediated and receptor-independent low density lipoprotein catabolism in type II hyperlipoproteinaemic subjects.
    Stewart JM; Packard CJ; Lorimer AR; Boag DE; Shepherd J
    Atherosclerosis; 1982 Sep; 44(3):355-65. PubMed ID: 6293516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of bezafibrate on the high-density lipoprotein subfractions HDL2 and HDL3 in primary hyperlipoproteinemia type IV.
    Schwandt P; Weisweiler P
    Artery; 1980; 7(6):464-70. PubMed ID: 7236016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of familial hypercholesterolemia with a combination of bezafibrate and guar.
    Wirth A; Middelhoff G; Braeuning C; Schlierf G
    Atherosclerosis; 1982 Dec; 45(3):291-7. PubMed ID: 7159500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Bezafibrate and delayed action etofibrate in hyperlipidemia].
    Lang PD; Vollmar J
    Dtsch Med Wochenschr; 1983 Feb; 108(8):302-5. PubMed ID: 6825604
    [No Abstract]   [Full Text] [Related]  

  • 9. Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia.
    Olsson AG; Orö L
    Atherosclerosis; 1982 Apr; 42(2-3):229-43. PubMed ID: 6951582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of uremic hypertriglyceridaemia with bezafibrate.
    Norbeck HE; Anderson P
    Atherosclerosis; 1982 Aug; 44(2):125-36. PubMed ID: 7138614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of bezafibrate on lipid and apoprotein levels in patients with idiopathic hypertriglyceridemia].
    Naruszewicz M; Nowicka G; Szostak WB; Kłosiewicz-Latoszek L
    Kardiol Pol; 1982; 25(7-8):527-31. PubMed ID: 7169740
    [No Abstract]   [Full Text] [Related]  

  • 12. The effect of bezafibrate and clofibrate on cholesterol ester metabolism in rabbit peritoneal macrophages stimulated with acetylated low density lipoproteins.
    Hudson K; Mojumder S; Day AJ
    Exp Mol Pathol; 1983 Feb; 38(1):77-81. PubMed ID: 6832340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholesteryl ester transfer activity in liver disease and cholestasis, and its relation with fatty acid composition of lipoprotein lipids.
    Iglesias A; Arranz M; Alvarez JJ; Perales J; Villar J; Herrera E; Lasunción MA
    Clin Chim Acta; 1996 Apr; 248(2):157-74. PubMed ID: 8740580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bezafibrate treatment in primary hypercholesterolaemia. Possibility of intermittent treatment.
    Fringes B; Riede UN; von Deimling O
    Atherosclerosis; 1982 Sep; 44(3):391-2. PubMed ID: 7150401
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia.
    Kłosiewicz-Latoszek L; Szostak WB
    Eur J Clin Pharmacol; 1991; 40(1):33-41. PubMed ID: 2060543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Lipid-lowering effect of etofibrate, bezafibrate and xanthinol nicotinate in patients with hyperlipoproteinemias].
    Machalke K; Djaja S; Richter E
    Ther Ggw; 1982 May; 121(5):301-11. PubMed ID: 6953613
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical experience with bezafibrate.
    Schubotz R; Schneider J; Hausmann L; Mühlfellner G; Mühlfellner O; Kaffarnik H
    Artery; 1980; 8(6):553-9. PubMed ID: 7259534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interruption of long-term lipid-lowering treatment with bezafibrate in hypertriglyceridaemic patients. Effects on lipoprotein composition, lipase activities and the plasma lipid fatty acid spectrum.
    Vessby B; Lithell H
    Atherosclerosis; 1990 May; 82(1-2):137-43. PubMed ID: 2360915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of a low-cholesterol, high-polyunsaturate diet on serum lipid levels, apolipoprotein B levels and triglyceride fatty acid composition.
    Durrington PN; Bolton CH; Hartog M; Angelinetta R; Emmett P; Furniss S
    Atherosclerosis; 1977 Aug; 27(4):465-75. PubMed ID: 196606
    [No Abstract]   [Full Text] [Related]  

  • 20. [The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].
    Noseda G; Fragiacomo C; Weidmann P; Bachmann C
    Schweiz Med Wochenschr; 1980 Dec; 110(49):1875-7. PubMed ID: 7455660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.